Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study

Márta Csatordai; Ria Benkő; Mária Matuz; Zsófia Engi; Dezső Csupor; Csaba Lengyel; Péter Doró

doi:10.1186/s13098-024-01334-8

Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study

Diabetol Metab Syndr. 2024 Apr 24;16(1):88. doi: 10.1186/s13098-024-01334-8.

Authors

Márta Csatordai^{1

2}, Ria Benkő^{1

2}, Mária Matuz^{1

2}, Zsófia Engi¹, Dezső Csupor¹, Csaba Lengyel³, Péter Doró⁴

Affiliations

¹ Faculty of Pharmacy, Institute of Clinical Pharmacy, University of Szeged, Szikra utca 8, 6725, Szeged, Hungary.
² Albert Szent-Györgyi Health Centre, Central Pharmacy, University of Szeged, Szeged, Hungary.
³ Albert Szent-Györgyi Health Centre, Department of Internal Medicine, University of Szeged, Szeged, Hungary.
⁴ Faculty of Pharmacy, Institute of Clinical Pharmacy, University of Szeged, Szikra utca 8, 6725, Szeged, Hungary. doro.peter@szte.hu.

Abstract

Background: The prevalence of diabetes is increasing, and several new drug groups have been authorized and used successfully in the treatment of diabetes, while older drug groups are still in use. Our aim was to assess the utilization tendencies and regional differences in antidiabetic medication consumption in Hungary between 2015 and 2021 and to identify the possible determinants of regional differences in antidiabetic medication use.

Methods: For this retrospective drug utilization study, yearly wholesale database was used, which provides total coverage for ambulatory antidiabetic drug sales in Hungary, including both reimbursed and non-reimbursed medications. Data were expressed as Defined Daily Dose per 1000 inhabitants per day (DDD/TID), percentage of total use and the ratio of the highest and lowest utilization values among the counties (max/min ratio). To assess the potential reasons for regional differences in antidiabetic drug use, we analyzed the associations between regional drug utilization data and possible determinants.

Results: The total national antidiabetic medication use has increased by 7.6% and reached 94.8 DDD/TID in 2021. Regarding antidiabetic subgroups, the use of metformin and novel antidiabetics (DPP4Is, GLP1As and SGLT2Is) and their combinations increased in all counties, while sulfonylurea consumption decreased, and insulin use was stable. In 2021, 19.2-24.1% of the total antidiabetic medication consumption was novel antidiabetics, 39.1-47.2% metformin, 14.8-25.8% sulfonylureas and 23.6-30.5% were insulins. Regional differences in antidiabetic medication consumption were considerable mainly in the case of GLP1As (max/min ratio:3.00), sulfonylureas (2.03) and SGLT2Is (1.92) in 2021. The association between antidiabetic medication use and possible determinants was confirmed in the case of unemployment rate and sulfonylurea use, the number of public medical card holders per ten thousand inhabitants and human insulin and sulfonylurea use. GLP1As were the only antidiabetic drug group that did not correlate with any of the investigated factors.

Conclusions: Although novel antidiabetic drug use was growing dynamically in Hungary, sulfonylurea use is still considerable. Differences in antidiabetic drug consumption were substantial between the regions.

Keywords: Antidiabetics; Diabetes mellitus; Drug utilization; Glucagon-like peptide-1 analogues; Hungary; Regional differences; Sodium-glucose co-transporter 2 inhibitors; Sulfonylureas.